NXTC Stock Overview
A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NextCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.97 |
| 52 Week High | US$2.57 |
| 52 Week Low | US$0.87 |
| Beta | 0.61 |
| 1 Month Change | -18.49% |
| 3 Month Change | -30.71% |
| 1 Year Change | -15.65% |
| 3 Year Change | -84.30% |
| 5 Year Change | -98.35% |
| Change since IPO | -95.13% |
Recent News & Updates
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation
Nov 13
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Jul 17Recent updates
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation
Nov 13We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Jul 17We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17Shareholder Returns
| NXTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | -3.6% | -2.4% |
| 1Y | -15.7% | -2.7% | 23.3% |
Return vs Industry: NXTC underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: NXTC underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| NXTC volatility | |
|---|---|
| NXTC Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NXTC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NXTC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Michael Richman | www.nextcure.com |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
NextCure, Inc. Fundamentals Summary
| NXTC fundamental statistics | |
|---|---|
| Market cap | US$27.17m |
| Earnings (TTM) | -US$58.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs NXTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$58.52m |
| Earnings | -US$58.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NXTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NextCure, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Alec Stranahan | BofA Global Research |
| null null | BTIG |